Streamlining Precision Oncology Testing Protocols: Lung Cancer as the Exemplar
Summary
July 14, 2026
Streamlining Precision Oncology Testing Protocols: Lung Cancer as the Exemplar
Molecular testing in lung cancer is extremely important in determining therapeutic regimens for patients diagnosed with this disease. Having the information available early in treatment planning allows for the most precise care, better efficacy and reduced side effects. More institutions are streamlining biomarker testing in lung cancer in order to provide patients and oncologists with rapid information for therapeutic planning. Streamlined testing can also improve tissue utilization, potentially reducing the need to re-biopsy. This webinar on July 14 at 1 pm ET will discuss why institutions should consider streamlining molecular biomarker testing, focusing both on advantages and potential problematic issues. Lung cancer will be used as the example, with the potential for application in a wide variety of tumor types.
This webinar is the first in a four-part series.
Molecular testing in lung cancer is extremely important in determining therapeutic regimens for patients diagnosed with this disease. Having the information available early in treatment planning allows for the most precise care, better efficacy and reduced side effects. More institutions are streamlining biomarker testing in lung cancer in order to provide patients and oncologists with rapid information for therapeutic planning. Streamlined testing can also improve tissue utilization, potentially reducing the need to re-biopsy. This webinar on July 14 at 1 pm ET will discuss why institutions should consider streamlining molecular biomarker testing, focusing both on advantages and potential problematic issues. Lung cancer will be used as the example, with the potential for application in a wide variety of tumor types.
This webinar is the first in a four-part series.